Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $300,004 | $301,965 | $279,037 | $266,257 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Cost of Goods Sold | $128,977 | $123,256 | $112,950 | $109,671 |
| Gross Profit | $171,027 | $178,709 | $166,087 | $156,586 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| R&D Expenses | $24,103 | $25,416 | $28,297 | $26,377 |
| G&A Expenses | $87,967 | $91,529 | $96,257 | $84,499 |
| SG&A Expenses | $87,967 | $91,529 | $96,257 | $84,499 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $12,077 | $23,223 | $44,623 | $9,824 |
| Operating Expenses | $124,147 | $140,168 | $169,177 | $120,700 |
| Operating Income | $46,880 | $38,541 | -$3,090 | $35,886 |
| % Margin | 15.6% | 12.8% | -1.1% | 13.5% |
| Other Income/Exp. Net | $601 | -$8,667 | -$2,709 | -$270 |
| Pre-Tax Income | $47,481 | $29,874 | -$5,799 | $35,616 |
| Tax Expense | $11,628 | $3,171 | $9,184 | $8,427 |
| Net Income | $36,256 | $26,642 | -$14,948 | $27,218 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS | 103.98 | 72.59 | -38.58 | 68.07 |
| % Growth | 43.2% | 288.2% | -156.7% | – |
| EPS Diluted | 103.68 | 72.37 | -38.58 | 67.97 |
| Weighted Avg Shares Out | 349 | 367 | 387 | 400 |
| Weighted Avg Shares Out Dil | 350 | 368 | 387 | 400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,002 | $1,572 | $1,153 | $2,543 |
| Interest Expense | $2,716 | $2,664 | $1,499 | $1,209 |
| Depreciation & Amortization | $8,812 | $18,178 | $17,249 | $17,055 |
| EBITDA | $59,009 | $50,716 | $12,949 | $52,930 |
| % Margin | 19.7% | 16.8% | 4.6% | 19.9% |